A total of 396 men with nonmetastatic (n = 139) or metastatic (n = 257) CRPC were randomly assigned to enzalutamide 160 mg per day (n = 198) or bicalutamide 50 mg per day (n = 198). Androgen ...
Circulating endothelial progenitor cells as biomarker for anti-angiogenic therapy with sunitinib and docetaxel in prostate cancer patients. Antitumor activity of sequential treatment with tyrosine ...
TAK-700 plus ADT improved responses and progression-free survival compared with bicalutamide plus ADT. TAK-700 plus androgen deprivation therapy (ADT) did not provide an overall survival (OS) benefit ...
Black men with metastatic hormone-sensitive prostate cancer may have better outcomes if they receive enzalutamide rather than bicalutamide in combination with androgen deprivation therapy, data from a ...
Adding hormone therapy to radiation therapy after surgery showed significant survival improvements in a recent study involving men with recurrent prostate cancer. Survival was improved in patients ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results